Medical cannabis is a dynamic and fast-moving market, and of increasing interest to many Pharma and Big Tobacco marketers. In North America and Europe, several countries now allow, or are considering allowing, the medical use of cannabis or cannabinoids in some form, while CBD supplements are widely available.
Already in 2019 we’ve also seen new developments in this field in the Middle East and Asia-Pacific, with Israel’s Parliament, the Knesset, agreeing to the export of medical cannabis. Once the decision is formally approved by the Cabinet, this will allow Israel to participate in the rapidly expanding global cannabis market, and exports may begin in mid-2019. As for Thailand, its National Legislative Assembly has just passed the second and third readings of an amendment to the Narcotics Bill to allow the production, import, export, possession and use of cannabis and kratom products for medical and research purposes.
One notable recent launch in the USA was Foria Basics Suppositories, a cannabidiol-based product formulated primarily to relieve menstrual cramps and discomfort. It also claims to relieve menopausal symptoms, inflammation and pain. The all-natural formula, which also includes 100% organic fair trade cocoa butter, delivers broad-spectrum CBD 100mg directly to the muscle and vascular tissues of the upper vagina and uterus. What’s unique about Foria Basics Suppositories is not just the delivery format, but also the menstrual pain positioning.
Medical cannabis was one of the hot OTC innovation trends of 2018, and Nicholas Hall’s OTC New Products Tracker now lists over 100 medical cannabis launches in its ever-growing archive. In 2018, we tracked 66 medical cannabis innovations, the majority emanating from the US market, followed by Germany and UK.
Stay informed about the latest cannabis-related scientific and regulatory developments by subscribing to our sister publication OTC.NewDirections — the reliable source from NHC to keep up with all relevant developments in this fast-developing market worldwide. For more details, or to arrange a trial subscription, please contact melissa.lee@NicholasHall.com